there's 27 million shares outstanding - so we're talking about a dilution of 0.04% !! It's nothing. Stop your ranting. Buy the dip. Shorts are scared of a squeeze - looks like that's you too.
At consensus peak sales of $2B for the Parkinson's market alone (not counting Alz or other future possible sales), ACAD trades at only P/S = 2. That's extremely cheap for biotechs. And with the safety and efficacy profile it has, and the selloff before the announcement into the 30's, this is a strong "buy" right here. Never mind it might go down another half point or so into the close, due to risk-off before China opens again. At least, you should all be nibbling as it edges lower today. The short-bashers out there are just trying to get your shares cheap - don't be a sucker.
thanks. Yes, black humor indeed. Solar-loving congress. Yup. Still, that's 15 months away. SEDG's guidance was pretty strong, and the valuation analysis given in SA made a good case that 32 was quite a reasonable and cheap share price. So it surprises me that buyers aren't coming in down here. I can't believe it's still the knee-jerk low oil means forget solar. Solar panels are quite competitive and prices are still dropping.
Just technicals - It dropped from 25.3 to 22.3 on nothing, that's a 10% drop. I'm guessing it'll at least hit 24 or 24.4 before resuming any downtrend given no news is driving this. I expect it's just a general profit-taking of small biotechs.
heading in to the last hour; expect hyperventilating shorts to start covering. Fell below support today, and that's a reliable place to see a bounce. Look at any stock chart you want and thats what you see more often than not.
I can't figure out why we're still in the 40's. Guidance of $3.50 for the year, vs mid 2's expectation? And the EPS on full year and in AH at a subterranean 14? And with Big Oil losing the climate wars, this should be over 50 easy, and maybe 60 given the future beyond. I've seen this sort of thing before, the clueless retail investors taking their 10% profits and running, while the smart money during the regular hours the next day look at the numbers and price it properly. I'll hang on and wait.
The worry had been that the Alzheimer's conference would have blockbuster news on a cure or major disease-modifying results from these big players. Now that we know the news is .... meh.... that's good for ACAD and it's ongoing trials for symptom relief. We may chop around here in the high 40's low 50's, but they're still a prime company to receive an offer - still a tiny company with a can't miss drug about ready to launch.
I agree. I can only wonder that perhaps there's interest on the part of the institutions to keep prices low as they can until they can hit they buy program. Makes no sense it's sitting at 34. Yahoo finance says 80% owned by institutions. Don't give away your shares on the fall from 35.1 to 33.9 in AH. Nothing in the CC justifies anything but further gains.
Much better play is CRUS, which is at PEG of 0.63, fwd PE of only 12, and just beat revs by 25%, beat similar on fwd Q2 revs, Beat on earnings, and already had sold off on AAPL fall. It's a value AND growth play. Risk/reward says buy
so? That just meets - why the hell is the stock up 10% or more? I suppose the selloff a month ago anticipating another horrendous quarter. Tough to buy into a short-covering panic by individual investors in the thin AH Pass. Good luck you guys.
I did something I rarely do - I payed up in AH for this stock, which has been whacked by the AAPL "disappointment"; artificial, as AAPL had a good quarter, just not as spectacular as momo's had hoped. This can easily get back to 38 before hitting overhead resistance. Revs beat, Rev projections beat, Earnings beat, and AAPL rising again in AH as well. Buy more, now that it dipped back to the low 34's for a moment.
why pay off debt when int rates so low? Buyback makes more sense. 8% of shares short, and it's only gotten back to the levels where some overhead resistance exists dating back a month. The separation of the equipment rental business is a bigger deal, though. That'll attract a much higher multiple, and they'll retain owership of shares. The risk/reward here is very good, even at 20.
I don't see anywhere in the announcement how many were in the study. 27% pos vs 23% positive in control doesn't sound impressive to me, unless there's a thousand in the study. Did they start with a tiny cohort just so they could hope for some barely marginal lucky fluke in the right direction? Who knows how many patients were in this study?